Accent Microcell Limited (NSEI: ACCENTMIC)
Health Care · Pharmaceuticals · IN
Rs583.00
+7.19% today · +96.3% 1Y
Accent Microcell Limited (NSEI: ACCENTMIC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $146.26M and employs 260 people.
Over the last twelve months the share price has gained 96.3%, trading between 238.00 and 585.00.
Tweenvest scores Accent Microcell Limited across four factors: quality 66/100, value 20/100, growth 95/100, dividend 41/100. Its strongest factor is growth.
ACCENTMIC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $146.26M
- Revenue (TTM)
- $37.30M
- P/E
- 31.26
- EPS
- 18.65
- Dividend yield
- 0.17%
- Beta (5Y)
- 0.24
- 52-week high
- Rs585.00
- 52-week low
- Rs238.00
- Avg volume (3M)
- —
- Shares outstanding
- 23.99M
- Employees
- 260
- Next earnings
- —
About Accent Microcell Limited
Accent Microcell Ltd. engages in manufacturing of pharmaceutical products. It manufactures Microcrystalline Cellulose (“MCC”) which is an odourless, fine white powder & a purified form of cellulose derived from refinement of highly purified wood pulp. The firm widely uses its MCC as texturizer, anticaking agent, binder, lubricant, a bulking agent, diluent with wide range of applications in Pharmaceutical, Nutraceutical, Food, Cosmetic and other industries. Its brands include Accel, Acrocell, Maccel and Vincel. The company was founded by Vasant Vadilal Patel, Ghanshyam Arjanbhai Patel, and Nitin Jasvantbhai Patel on April 10, 2012 and is headquartered in Ahmedabad, India.
- ISIN
- INE0Q5D01013
- Founded
- 2001
- Listed since
- Dec 15, 2023
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.